What question did this study set out to answer?

To establish a rational basis for antithrombotic prophylaxis and treatment with aspirin by integrating basic molecular mechanisms with clinical pharmacological data and randomized trial evidence.

May 5, 1994New England Journal of Medicine

Aspirin as an Antiplatelet Drug

View Full Paper

Ask AI

Bookmark

To establish a rational basis for antithrombotic prophylaxis and treatment with aspirin by integrating basic molecular mechanisms with clinical pharmacological data and randomized trial evidence.
Reviewed pathophysiologic mechanisms of vascular occlusion and platelet activation.
Synthesized molecular pharmacology data detailing aspirin's mechanism of action on platelet function.
Evaluated outcomes and clinical evidence from randomized clinical trials of aspirin and related antiplatelet agents.
Aspirin produces a persistent functional defect in platelets that inhibits platelet aggregation.
Pharmacologic and clinical trial data support the efficacy of aspirin for antithrombotic prophylaxis and acute management of vascular occlusive events.

Structured PICO

Intervention

Aspirin

This review describes the rational basis for antithrombotic prophylaxis and treatment with aspirin, integrating its molecular mechanism of action with clinical pharmacologic data.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May guide antithrombotic decisions with mechanistic clarity; leaves open optimal integration with contemporary regimens.

Cite This Study

Wood et al. (1994) studied this question.

synapsesocial.com/papers/6a0341901e37aa8cc46506d9 https://doi.org/10.1056/nejm199405053301808

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Aspirin as an Antiplatelet Drug

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Aspirin as an Antiplatelet Drug

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider